Major Depressive Disorder
Conditions
Interventions
Experimental group:Repetitive transcranial magnetic stimulation (rTMS) combined with transcranial direct current stimulation (tDCS)
Sponsors
Beijing Anding Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients aged 18-60 years; 2. After the M.I.N.I.6.0.0 interview, meet the diagnostic criteria of the American Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) for major depressive disorder, with single or repeated episodes. 3. HAMD-17 >= 14 points at baseline.
Exclusion criteria
Exclusion criteria: 1. History of neurological diseases, including head trauma, epilepsy, encephalitis, brain tumor, etc.; 2. Those who currently meet the diagnosis of other important psychiatric disorders, including neurocognitive disorders, neurodevelopmental disorders, schizophrenia, bipolar disorder, secondary depression, obsessive-compulsive disorder, panic disorder, PTSD, alcohol (or drug) dependence or abusers, personality disorders; 3. There is a high risk of suicide, defined as HAMD-17 item 3 >= 3 points; 4. Patients with moderate or above abnormal EEG, or mild abnormal EEG with clinical significance; 5. Major physical disease or unstable physical condition; 6. Abnormal items in the patient's vital signs, laboratory examinations, and electrocardiogram examinations, which the investigator judges have significant clinical significance and will affect the patient's safety or test results; 7. Those with metal implants, pacemakers, and metal arterial clips in the body; 8. Those who have received ECT, TMS, VNS, DBS or light therapy within 3 months before screening; 9. Patients with treatment-resistant depression, defined: 2 antidepressants have insufficient therapeutic efficacy; insufficient efficacy is defined as an improvement in the severity of major depressive disorder symptoms assessed by the Antidepressant Treatment Response Questionnaire (ATRQ) <50%. Adequate antidepressant treatment is defined as receiving antidepressant treatment at the lowest dose (or higher dose) as detailed in the ATRQ for a duration of at least 6 weeks; 10. Those who have taken antidepressants, mood stabilizers, antipsychotics, anxiolytics and benzodiazepines within two weeks before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of adverse event and advers reaction;laboratory test;response rate;remission rate;depression symptom rapid self-rating scale score;generalized anxiety self-rating scale;anxiety; | — |
Countries
China
Contacts
Public ContactWang Zhimin
Beijing Anding Hospital Affiliated to Capital Medical University
Outcome results
None listed